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Introduction
In the United States (US), penile cancer (PC) is a relatively 
rare malignancy with an estimated incidence of 2,320 cases 
in 2018 and nearly 400 deaths (1). Approximately 35–40% 
of patients with PC will present with ≥ clinical T2 disease 
(2,3). In developing countries, with large income disparities 
and those with low rates of circumcision, the incidence 
of PC is far greater (4). Rural India has three times the 
incidence of the US, and in Brazil the rate of new PCs may 
reach 8.3 per 100,000 men (5). When men with PC present 
for treatment, accurate staging is critical for prognostic 
and therapeutic information (6). Early identification and 
surgical removal of inguinal lymph nodes (ILNs) may 
increase survival in men with metastatic disease (7). On the 
contrary, men with advanced and potentially unresectable 
nodal disease may be better suited with neoadjuvant 
chemotherapy or radiation therapy (8). When considering 
disease spread to ILNs, the most important prognostic 
factor is the stage and grade of the penile lesion (9,10). 
Low-grade and stage (≤ pT1a) tumors have positive ILN 
rates under 10% while high-grade (≥ pT1b) tumors may 
metastasize to inguinal nodes in up to 75% of cases (11). 
Having these risk factors, along with palpable disease 
in the inguinal region, should heighten the physician’s 
clinical suspicion for lymphatic spread (9,10). An important 
caveat is that an examination of the inguinal area is often 
unreliable, especially in overweight individuals, resulting 
in many false negatives and false positives (12,13). Because 
of this, clinicians often rely on imaging modalities to better 
stage patients prior to treatment (13,14). 
Urologists must be aware of the extent of metastatic spread 
as this is the most important factor predictive of survival (15). 
Multiple studies have found average 5-year disease-free 
survival rates of 85–100%, 79–89%, 17–60%, and 0–17% for 
pN0, pN1, pN2, and pN3, respectively (Table 1) (6,12,16,17). 
PC has a predictable pattern of metastatic spread: first 
spreading to the sentinel lymph node (SLN) which is often 
located within the superficial lymph nodes near the central 
and superior aspects of the saphenofemoral junction (18,19). 
Metastases to inferior and deeper inguinal nodes and then 
pelvic nodes may occur later (18). This review will highlight 
the indications and available imaging modalities for detecting 
inguinal and pelvic nodal metastases in the setting of PC. 
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Indications for imaging
Inguinal imaging is not required for all men with PC. 
The National Comprehensive Cancer Network (NCCN) 
guidelines indicate imaging in two clinical situations prior 
to treatment: in patients with intermediate or high-risk 
PC (clinical stage ≥ T1b) or in all men with palpable ILNs 
on physical exam (8). These guidelines suggest obtaining 
either computed tomography (CT) or magnetic resonance 
imaging (MRI), with contrast if possible, of the abdomen 
and pelvis, as well as chest imaging (8). In men who have 
undergone surgical inguinal lymphadenectomy for pN2-
3 disease, surveillance imaging (CT or MRI) is indicated 
every three months for the first year and then every 6 
months thereafter. For patients with unresectable inguinal 
disease who undergo chemotherapy or radiation therapy as 
neoadjuvant or primary treatment, repeat CT or MRI of the 
abdomen and pelvis along with lung imaging is indicated 
after treatment. In such a clinical scenario, clinicians may 
consider positron emission tomography (PET)/CT as this 
modality may have superior diagnostic performance over 
conventional cross-sectional imaging (8). 
Conventional imaging
Conventional cross-sectional imaging, such as CT or MRI, 
often relies on size criteria (e.g., >8–10 mm) to diagnose 
metastatic spread to lymph nodes. However, based solely on 
size criteria, a significant number of cancerous nodes may 
go undiagnosed while benign enlarged nodes may be falsely 
positive (Figure 1) (20). PC is known to cause inflammatory 
changes in local nodes explaining a notoriously high rate of 
false positives findings (21). 
Graafland et al. looked at their experience with CT 
imaging to detect metastatic spread to inguinal and pelvic 
lymph nodes using different radiologic criteria to identify 
suspicious nodes. In patients with low risk for inguinal 
nodal involvement, an 8 mm cut-off in the short axis of the 
node provided the highest accuracy for predicting a positive 
node with a sensitivity of 87% and specificity of 81% (22). 
For patients at high risk of inguinal nodal disease, the 
criteria with the highest accuracy (88%) was the presence of 
an irregular nodal border which had an improved specificity 
of 95% (22). For high-risk patients, a cut off of 8 mm or 
greater in the short axis yielded a sensitivity of 95% but 
at the expense of specificity at just 54%. This threshold 
measurement, 8 mm, also provided high sensitivity 
(100%) when ruling out ipsilateral pelvic nodal disease but 
decreased with increasing lymph node diameters (22). 
MRI is another cross-sectional imaging technique to 
stage ILNs. Lucchesi et al. found 13 of 15 (86.7%) cases 
of ILN involvement using MRI compared to physical 
exam which identified just 7 of the 15 (46.7%) nodes (23). 
MRI may not provide significant additional information 
over CT scans for ILN imaging but MRI may provide 
Table 1 Definitions of pathological staging of inguinal lymph nodes for penile cancer (8) 
Staging Definition
Clinical stage
cNX Regional lymph nodes cannot be assessed
cN0 No palpable or visibly enlarged inguinal lymph nodes
cN1 Palpable mobile unilateral inguinal lymph node
cN2 Palpable mobile ≥2 unilateral inguinal lymph nodes or bilateral inguinal lymph nodes
cN3 Palpable fixed inguinal nodal mass or pelvic lymphadenopathy unilateral or bilateral
Pathologic stage
pNX Lymph node metastasis cannot be established
pN0 No lymph node metastasis
pN1 ≤2 unilateral inguinal metastases, no ENE
pN2 ≥3 unilateral inguinal metastases or bilateral metastases
pN3 ENE of lymph node metastases or pelvic lymph node metastases
ENE, extranodal extension.
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additional information when staging the primary tumor 
(Figure 2) (24). MR images of the primary penile tumor are 
optimally obtained after intracorporeal injection (ICI) of 
10 µg of prostaglandin E1 with axial, sagittal and coronal 
images then obtained (25). Gadolinium contrast may help 
to identify lymph nodes but only T1- and T2-weighted 
images are necessary to evaluate penile anatomy and tumor 
extension (25). MRI of the penis shows the muscular 
wall of the urethra, tunica albuginea, and Buck’s fascia to 
all be hypointense on both T1 and T2 weighted images 
while the corpora cavernosa and corpus spongiosum have 
intermediate signal intensity on T1-weighted imaging 
and high signal intensity on T2-weighted imaging (25). 
Hanchanale et al. studied 100 patients with clinical T1–T3 
PC using MRI after prostaglandin E1 ICI and found MRI 
to have a sensitivity and specificity for tunica albuginea 
invasion of 82.1% and 73.6%, respectively (26). The 
sensitivity and specificity of urethral invasion was 62.5% 
and 82.1% in this study (26). 
A unique approach to MR imaging utilizes a novel 
contrast agent, ultra-small superparamagnetic iron oxide 
particles (USPIO) such as ferumoxtran-10 or commercially 
available ferumoxytol. The former has a half-life of 25 hours 
while the latter has shorter half-life of 14–15 hours and is 
less prone to allergic reactions (20,27). Ferumoxtran-10 
A B
C D
Figure 1 CT scans demonstrating a false-positive and true-positive when staging ILN. A 32-year-old man with HgT2 penile cancer 
invading into the glans with imaging demonstrating a 2.6 cm left inguinal node (arrow) (A) and 1.9 cm left external iliac node (arrow) (B) 
all of which were benign after robotic-assisted node dissection. An 82-year-old man with HgT2 penile cancer with 2.2 cm left inguinal 
node (arrow) (C) with irregular borders and 1.8 cm left external iliac node (arrow) (D). Inguinal lymph node dissection was performed with 
pathology demonstrating metastatic disease with tumor necrosis and extranodal extension.
Figure 2 A 47-year-old male with penile cancer. Sagittal T2W MR 
image shows a large heterogenous mass involving almost the entire 
penis (red bracket).
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nanoparticles are taken up within the penile lymphatics, 
phagocytosed by resident macrophages, and results in nodal 
accumulation of contrast (20). Metastatic nodes are often 
lacking in macrophages and therefore accumulate less of 
this nanoparticle (20). Nanoparticles within a benign lymph 
node result in a decreased T2* (susceptibility weighted) 
images along with bright T2 images. In contrast, malignant 
nodes will have bright T2 and T2*-weighted images 
(Figure 3) (20). This technology has been utilized for 
multiple cancers and has been proven effective for PC as 
well (28,29). Tabatabaei et al. studied ferumoxtran-10 in 
seven men with stage T1b–T2 PC and found a sensitivity 
of 100%, specificity of 97%, positive predictive value of 
81.2%, and negative predictive value of 100% (29).
SLN biopsy
The original lymph drainage of the penis was described 
in  1977 by  Ramon Cabanas  who per formed 100 
lymphangiograms (LAGs) in men with both benign and 
malignant penile lesions (19). In such LAGs, the SLN was 
mapped to the antero-medial border of the epigastric-
saphenous junction which was therefore recommended to 
be resected based on anatomical landmarks. Furthermore, 
in 31 cases where SLN biopsy was negative, there was no 
disease recurrences within 3- and 5-year overall survival 
rate was 90% (19). Despite this promising data, additional 
studies showed that the use of Cabanas’ anatomic landmarks 
alone may yield false-negative findings due to altered 
lymphatic drainage (30,31).
Due to the risk of false-negative results in SLN biopsies, 
physicians turned to other, real-time methods to identify 
lymphatic drainage combining dynamic sentinel node biopsy 
(DSNB) techniques used to diagnose other malignancies (32). 
Isosulfan blue dye travels through the lymphatic channels 
allowing surgeons to visualize channels intraoperatively 
and had previously been used in malignant melanoma to 
visualize the SLN (32). Furthermore, Krag et al. developed 
a technique of using a gamma-ray detector after injection 
of a radiolabeled technetium (99mTc)-nanocolloid for 
localization of the SLN in breast cancer (33). Horenblas 
et al. first combined these procedures and performed LSG 
on 55 patients with T2–T3 PC disease using both blue dye 
and a radiolabeled 99mTc-nanocolloid (34). One day prior to 
surgery, 99mTc-nanocolloid is injected near the tumor site 
and immediate dynamic imaging was performed, followed 
by static images at 30 minutes and 2 hours post injection 
(Figure 4). These locations were marked on the patient’s 
skin to plan for surgery the following day. Blue dye was then 
injected in a similar manner immediately prior to surgery to 
aid in intraoperative identification. In the initial series, only 
one patient had tumor recurrence after negative DSNB. A 
subsequent study of 250 more surgically explored groins 
found that the false-negative rate decreased from 19.2% to 
4.8% and the complication rate decreased from 10.2% to 
5.7% as these practitioners gained experience (35). 
DSNB is indicated in men with PC who are at 
intermediate to high risk of having metastases to the ILNs 
without palpable disease (6). This procedure should be 
done bilaterally with the goal of preventing the morbidity 
of bilateral ILN dissections (ILND). However, if the 
DSNB is positive, a complete ILND should be performed. 
Figure 3 An 84-year-old male with penile cancer. Axial T2*-weighted MR image shows an enlarged lymph node in the left inguinal region 
(arrow) (A). Axial T2*-weighted MR image obtained 24 hours after intravenous injection of ferumoxytol shows persistently high signal 
intensity within the left inguinal adenopathy (arrow) (B) which suggests metastatic involvement of penile cancer. Axial 18F-FDG-PET/CT 
image shows tracer uptake within the left inguinal adenopathy which confirms presence of metastasis (arrow) (C).
A B C
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Figure 4 A 38-year-old man with HgT1 penile cancer who underwent wide local excision of primary lesion. Axial CT imaging (A) 
demonstrates 2.8 cm right inguinal lymph node (arrow). 18F-FDG PET (B) image shows tracer uptake within the right inguinal adenopathy 
(arrow) which confirms presence of metastasis. Lymphoscintigraphy was performed (C) showing sentinel node corresponding with nodal 
mass (arrow). Inguinal lymph node dissection was performed with final pathology revealing 3.5 cm nodal metastasis and 9 benign lymph 
nodes. 
DSNB should only be performed at experienced centers to 
minimize the chance of a false-negative node result. 
The principle behind LSG was then merged with CT 
technology to perform single-photon emission computed 
tomography-CT (SPECT-CT). Leijte et al. performed both 
standard DSNB while at the same time performing SPECT-
CT at 2 hours post-injection of 99mTc-nanocolloid (18). 
Combining these techniques gave both the functional 
information of the lymphatic drainage and the spatial 
resolution of CT. The technique was performed in 86 
clinically negative groins and with the combination of 
both techniques, lymphatic drainage was demonstrated 
in 95.3%. SNL was not detected in the zones inferior 
to the saphenofemoral junction nor was there drainage 
directly into the pelvis (18). Another study of this combined 
technology showed SPECT/CT to have a high sensitivity 
and specificity of 88.8% and 86.7%, respectively (36). 
Another novel method of identifying the SLN and 
patterns of drainage requires a fluorescent dye, indocyanine 
green (ICG), which is injected near the primary lesion site 
prior to inguinal lymphadenectomy (37,38). Markuszewski 
et al. compared ICG to 99mTc-nanocolloid radiotracer which 
was injected with ICG prior to surgery and then used a 
gamma-ray detector and near infrared fluorescence (NIRF) 
camera to detect these compounds, respectively (38). 
Both methods of SLN biopsy were able to detect SLNs 
intraoperatively, including those with metastases (38). 
Robotic-assisted inguinal lymphadenectomy with a NIRF 
camera may become a more standardized approach in 
performing this procedure with comparable node yields 
and lower morbidity. ICG may become a more commonly 
utilized method of intraoperative identification of lymph 
nodes during such procedures (37,39). Furthermore, 
ICG and 99mTc-nanocolloid can be combined into one 
compound for hybrid approaches to first guide the surgeon 
via radiotracer mapping and then further intraoperative 
visualization with ICG (40).
Ultrasound (US) has also been used to assess inguinal 
nodes during the time of surgery. Kroon et al. performed 
fine-needle aspiration cytology (FNAC) prior to DSNB or 
inguinal node dissection in 83 clinically negative groins and 
found US with FNAC to have a sensitivity and specificity 
of 39% and 100%, respectively (41). Intraoperative US has 
also been applied to palpable nodal disease during DSNB 
to identify more metastatic nodes that were missed during 
DSNB possibly due to lymphatic channel blockage (42). 
Contrast-enhanced ultrasonography (CEUS) is another 
novel technique that has been used in other malignancies 
for sentinel node mapping but has yet to see use with PC. 
For example, breast cancer often utilizes a SLN biopsy 
and this technique was studied in 54 patients and found 
to have a sensitivity of 89% with all five cancerous nodes 
detected (43). Another example supports this concept when 
applied to ILNs. Lahtinen et al. found the sensitivity of 
the procedure to be 81.2% in identifying SLN from vulvar 
cancer, enabling complete resection intraoperatively (44). 
Another modality to evaluate metastatic lymph nodes 
in PC is PET imaging utilizing 18F-fluorodeoxyglucose 
(18F-FDG) which is taken up by malignant cells more 
rapidly (45). This functional imaging is then combined with 
the anatomic information obtained from CT (Figure 4). 
Souillac et al. compared the accuracy of 18F-FDG-PET/
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CT in both patients with clinically positive and clinically 
negative inguinal node exams (46). 18F-FDG-PET/CT 
was found to have a sensitivity of 75% and specificity of 
87.5% in clinically negative patients while the sensitivity 
was 37.5% and 97.2% in patients with clinically positive 
nodes (46). This low sensitivity highlights the importance to 
incorporate clinical suspicion, based on physical exam and 
tumor stage, into decision making. A meta-analysis of seven 
total studies showed an overall sensitivity of 80.9% and 
specificity of 92.4% for detection of lymph nodes. However, 
sensitivity varied based on clinical exam with an increase in 
sensitivity to 96.4% in clinically positive exams, decreasing 
to 56.5% in patients with negative exams (47). 
18F-FDG-PET/CT has additional value in predicting 
the nodal status outside of the groin. Graafland et al. 
evaluated 18 patients with metastatic spread to inguinal 
nodes and then underwent evaluation of their pelvic nodes 
and found a sensitivity of 91% and specificity of 100% (48). 
Another study of patients with advanced disease, all 
of whom had inguinal disease and 21/48 (43.8%) who 
presented with distant metastases found 18F-FDG-PET/
CT to have a sensitivity and specificity of 82% and 93%, 
and overall was able to detect 33% more metastatic lesions 
than cross-sectional imaging alone (49). 
Conclusions
Accurate staging of ILNs is important to administer the 
multiple modalities required in the treatment of PC and 
in the proper sequence. Conventional cross-sectional 
imaging such as CT and MRI rely mainly on size criteria 
to determine benign vs. malignant lymph nodes and may 
yield to false-negatives and positives. MRI may contribute 
an additional role in staging of the primary tumor. DSNB 
performed with radiotracers and dyes incorporates 
functional information and may yield false-negative rates 
as low as 5%. 18F-FDG-PET imaging is indicated in 
advanced disease and has high specificity and sensitivity 
which increases with stage. Many imaging and surgical 
methods are available to identify suspicious nodes but 
physicians’ clinical suspicion, based on the primary tumor 
grade and stage, should weigh heavily on management 
decisions. 
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